Funded Projects


  • Ronald Buckanovich, Combating Chemoresistance in Epithelia Ovarian Cancer: Development of Cancer Stem Cell Depleting ALDH1A1/1A2 Isozyme Selective Inhibitors as a Potential Adjunct to Chemotherapy
  • Vern Carruthers, Structure-based design of inhibitors targeting a key Toxoplasma gondii protease
  • Eugene Chen, Identification of small-molecule activators of KLF14 for treating atherosclerosis
  • Matthew Soellner, Development of UM-164: A dual c-Src/p38 kinase inhibitor for the treatment of triple negative breast cancer
  • Raymond Trievel, Methyltransferase Inhibition in Chronic Kidney disease


  • Maria do Carmo Costa, Identification of predisposing CNS-penetrant therapeutic compounds for Spinocerebellar Atazia Type 3
  • Vern Carruthers, HTS identification of cathepsin inhibitors for chronic toxoplasmosis
  • Amanda Garner, High-Throughput Platform Assay Technology for the Discovery of pre-microRNA-21-Selective Inhibitors
  • David Lombard, Identification and characterization of PAPP-A inhibitors
  • Zaneta Nikoslovska-Coleska, Mcl-1 inhibitors for the treatment of pancreatic cancer
  • Yoichi Osawa, High-Throughput Screening for small molecule activators of human Hsp70, a key component of a shaperone machinery that detects and degrades misfolded proteins.
  • Duxin Sun, Targeting RBBP4/7 in PRC2 as Therapeutic Strategy to Inhibit Tumor Initiating Cells in TNBC


  • Ronald Buckanovich, Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy
  • Gregory Dressler, Identifying Novel Small Molecules for Renal Disease
  • Eric C. Martens, A live cell screen for chemical inhibitors of colitis caused by commensal bacteria
  • George Garcia, Identification of Novel Inhibitors of MTB RNA Polymerase via HTS
  • John Tesmer, High-throughput screening for small molecule inhibitors directed against the PH domain of P-Rex1, an enhancer of metastatic potential
  • John Tesmer, Synthesis and Characterization of Hybrid Analogs for the Inhibition of G Protein-Coupled Receptor Kinase 2
  • Maria Sandkvist, High throughput screen for the identification of type II secretion inhibitors in Acinetobacter baumannii
  • Matthew Young, A non-active site directed approach to inhibit deubiquitinases for cancer therapy


  • Mark Day, Developmentof Inhibitory ADAM15 Probes for Evaluation by Proteolytic FRET
  • Joseph Holoshitz, Small-Molecular Shared Epitope Antagonistic Ligands: Validation of Virtual Screening Hits
  • Pavel Nagorny, Development of lactimidomycin-based cancer cell migration inhibitors
  • Peter Scott, Synthesis and Evaluation of High Affinity Radiotracers for PET Imaging of the Dopamine D3 Receptor
  • David Sherman, New Natural Product Antibiotics: Using HTS to Target the Bacterial Ribosome
  • Haoming Zhang, Antithrombotic potential of novel mixed disulfide conjugates of clopidogrel


  • Victor J. DiRita, Bacterial Virulence Traits as targets for Drug Development
  • Gregory R. Dressler, Identifying Novel pax2 Inhibitors for Renal Disease
  • Margaret E. Gnegy, CNS-Permeant Tamoxifen Derivatives for the Treatment of Amphetamine Abuse
  • Richard Neubig, Metabolic Stability of RGS4 Inhibitors
  • Zaneta Nikolovska-Coleska, Structural Characterization of the Interaction between MLL-Fusion Proteins and Histone Methyltransferase DOT1L
  • Yatrik Shah, Identifying HIRF2a specific transcriptional regulatory mechanisms
  • John Tesmer, Synthesis of More Potent and Selective Analogs of Paroxetine for the Inhibition of G Protein-coupled Receptor Kinase 2
  • Shaomeng Wang, Discovery of Small-Molecule Inhibitors of the EZH2-EED Protein-Protein Interaction by High-Throughput Screening